辛伐他汀对糖尿病大鼠尿蛋白排泄的影响被引量：7

The effect of simvastatin on the urinary protein excretion of diabetic rats

导出

摘要目的观察辛伐他汀对糖尿病大鼠尿蛋白排泄的影响,以了解其对糖尿病肾损害的保护作用。方法建立糖尿病大鼠模型,分为正常对照(A组)、糖尿病组(B组)、辛伐他汀治疗组(C组)。检测各组第2,4,8周血糖、尿视黄醇结合蛋白(RBP)、白蛋白(ALB)排泄率。结果第2,4,8周,B,C组尿ALB、RBP排泄率均高于A组(P<0.01),并随病程的延长不断增高,C组较B组有明显减少(P<0.01)。结论辛伐他汀对糖尿病大鼠肾小球和肾小管-间质损害有保护作用。 Objective To observe the effect of simvastatin on the urinary protein excretion of diabetic rats and find its renal protective effects. Method 24 rats were randomly assigned to normal control group （group A） ,diabetic rats group （group B） group and simvastatin treatment group （group C）. Blood glucose,the urinary excretion rates of albumin and retinal-binding protein（RBP） were tested at the 2nd,4th and 8th week. Results At the 2rid, 4th and 8th week,the urinary excretion rats of albumin and RBP in group B and C were higher than those of group A （P 〈 0.01 ）, and rose further as the nephropathy progressed, but which in group C were lower significantly than those of group B （ P 〈 0.01 ）. Condusion Simvastatin can play a protective role to glomerulus and renal tubule - interstitium of diabetic rats in some extent.

作者杨光伟李秀财叶山东范爱红陈燕胡闻陈柯王迎新

机构地区安徽医科大学附属省立医院安徽医科大学附属省立医院安徽高等医学专科学校

出处《中国临床保健杂志》 CAS 2007年第1期62-64,共3页 Chinese Journal of Clinical Healthcare

基金安徽省教育厅自然科学研究资助项目(2006KJ318B)

关键词糖尿病肾病蛋白尿降血脂药药理作用模型动物 Diabetic nephropathies Proteinuria Antilipemic gents Pharmacologic actions Models, animal

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献9

1[1]Usui H,Shikata K,Matsuda M,et al.HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats[J].Nephrol Dial Transplant,2003,18(2):265-272.
2[2]Ota T,Takamura T,Ando H,et al.Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model[J].Diabetologia,2003,46(6):843-851.
3[3]Nogaki F,Muso E,Yashiro M,et al.Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells[J].Kidney Int Suppl,1999,71:S198-201.
4[4]Economides PA,Caselli A,Tiani E,et al.The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes[J].J Clin Endocrinol Metab,2004,89(2):740-747.
5[5]Kunieda Y,Nakagawa K,Nishimura H,et al.HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells[J].Thromb Res,2003,110(4):227-234.
6[6]Lopez S,Peiretti F,Bonardo B,et al.Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages[J].Cardiovasc Pharmacol,2001,37(6):762-768.
7[7]Wassmann S,Laufs U,Baumer AT,et al.Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells:involvement of angiotensin AT1 receptor expression and Rac1 GTPase[J].Mol Pharmacol,2001,59(3):646-654.
8[8]Amemiya T,Sasamura H,Mifune M,et al.Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells[J].Kidney Int,1999,56(6):2055-2063.
9[9]Vincent L,Chen W,Hong L,et al.Inhibition of endothelial cell migration by cerivastatin,an HMG-CoA reductase inhibitor:contribution to its anti-angiogenic effect[J].FEBS Lett,2001,495(3):159-166.